Navigation Links
Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Date:9/25/2007

to placebo in patients with major unipolar depressive disorder. The study, which has a treatment period of approximately two months, is being conducted at more than 35 centers across the U.S. and Canada.

Pharmacokinetic trials have demonstrated that Labopharm's once-daily formulation of trazodone has controlled-release properties over a 24-hour period.

Based on discussions with U.S. Food and Drug Administration (FDA), Labopharm expects to submit a New Drug Application (NDA) for its once-daily formulation of trazodone under Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act, which typically applies to reformulations of drugs that are already approved and being marketed, allowing the Company to leverage existing efficacy and safety data on trazodone. Under this Section of the Act, one positive Phase III study is required for the formulation to be approved by the FDA.

About Trazodone

Trazodone is an atypical anti-depressant that acts as a dual serotonin agonist and serotonin reuptake inhibitor (SARI). Trazodone appears to increase serotonin activity via three mechanisms: the activation of neuronal serotonin receptors; the inhibition at the neuronal serotonin feedback system which regulates the action of serotonin; and the inhibition of the re-uptake of serotonin. Trazodone also helps to treat depression by improving sleep as a result of sedative effects caused by activation of histamine receptors and initiation and restoration of deep sleep cycles as a result of serotonin receptor activation. This may be of clinical benefit in depressed patients who have agitation, insomnia or poor sleep quality associated with their depression. Depression is one of the most prevalent central nervous system disorders, affecting at least 121 million people globally. Trazodone is widely used in its treatment with more than 14 million prescriptions written in the U.S. alone in 2006.

About Labopharm's Once-Daily Formulation of Trazodone

I
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. SARS-Free Taiwan to Mark End Phase of Global Fight
6. S. Africa AIDS in death phase
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. Phase 1 Drug Trials on Humans to Be Made Public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... dangerous atrial fibrillation , , WEDNESDAY, Sept. 5 (HealthDay News) -- ... abnormal heartbeat called atrial fibrillation. , The drug, dronedarone, is ... but has proven effective in two major trials, with fewer ... the Sept. 6 issue of the New England Journal ...
... Discoveries could lead to new treatments for autoimmune diseases, scientists ... boost the risk of painful rheumatoid arthritis, and one of ... new reports. , In one report, a variant of the ... genes now identified to increase the risk of developing rheumatoid ...
... have an East Valley location, CHANDLER, Ariz., Sept. 5 ... Village Health Club and Spa will,be built, this one in ... the land at the corner of Alma School and,Ocotillo Road ... The,purchase of the 7.3 acres in this growing part of ...
... Sept. 5 With only days,remaining in the 2007 ... Arnold Schwarzenegger, as well as state legislative,leaders, are awaiting ... health care coverage and the quality of care., ... about how AARP,members feel about the need for health ...
... is largest by an individual to a children,s hospital ... announced,today that philanthropist Ann Lurie has pledged $100 million ... Hospital in Chicago. This,gift is the largest given by ... The $100 million gift, the largest charitable investment ...
... Addresses the National Need for More Nurse Educators, ... Colleges of Nursing (AACN) is pleased to announce ... (J&J) is launching a new national,scholarship program designed ... minority backgrounds. The J&J-AACN Minority Nurse Faculty Scholars,program ...
Cached Medicine News:Health News:Drug, Pacemaker Fight Irregular Heartbeat 2Health News:Drug, Pacemaker Fight Irregular Heartbeat 3Health News:Genes Boost Risk for Rheumatoid Arthritis, Lupus 2Health News:Genes Boost Risk for Rheumatoid Arthritis, Lupus 3Health News:Genes Boost Risk for Rheumatoid Arthritis, Lupus 4Health News:Ocotillo in Chandler Will Have a Village 2Health News:AARP Poll: California Members Want Health Care Reform THIS YEAR 2Health News:Children's Memorial Hospital in Chicago Announces $100 Million Gift from Philanthropist Ann Lurie 2Health News:Children's Memorial Hospital in Chicago Announces $100 Million Gift from Philanthropist Ann Lurie 3Health News:Johnson & Johnson Campaign for Nursing's Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program 2Health News:Johnson & Johnson Campaign for Nursing's Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program 3Health News:Johnson & Johnson Campaign for Nursing's Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program 4
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... RICHMOND, Calif., Oct. 29 Transcept Pharmaceuticals (Nasdaq: ... Drug Administration (FDA) issued a Complete Response Letter regarding ... (zolpidem tartrate sublingual tablet). The NDA, submitted by ... Intermezzo® for use as-needed for the treatment of ...
... Corporation, makers of Praxis Electronic Medical Records (EMR), announced ... Datum, a tool that allows physicians to use free ... The Praxis Datum engine guarantees full qualification for Federal ... use, guidelines. , With Federal stimulus funds under the ...
Cached Medicine Technology:Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application 2Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application 3Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application 4Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application 5Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation 2
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Medicine Products: